Controls to Minimize Disruption of the Pharmaceutical Supply Chain During the COVID-19 Pandemic


_PDA J Pharm Sci and Tech_ **2020**, 74 468-494

Access the most recent version at doi:10.5731/pdajpst.2020.012021
ABSTRACT: This article reviews currently available scientific literature related to the epidemiology, infectivity, survival, and susceptibility to disinfectants of Coronaviruses, in the context of the controls established to meet good manufacturing practice (GMP) regulations and guidance, and the public health guidance issued specifically to combat the COVID-19 pandemic. The possible impact of the COVID-19 pandemic on the pharmaceutical supply chain is assessed and recommendations are listed for risk mitigation steps to minimize supply disruption to pharmaceutical drug products. Areas addressed include a brief history of the COVID-19 viral pandemic, a description of the virus, the regulatory response to the pandemic, the screening of employees, the persistence of the virus on inanimate surfaces, cleaning and disinfection of manufacturing facilities, the use of GMP-mandated personal protective equipment to counter the spread of the disease, the role of air changes in viral clearance, and approaches to risk assessment and mitigation. Biological medicinal products have a great record of safety, yet the cell cultures used for production can be susceptible to viruses, and contamination events have occurred. Studies on SARS-CoV-2 for it ability to replicate in various mammalian cell lines used for biopharmaceutical manufacturing suggests that the virus poses a low risk and any contamination would be detected by currently used adventitious virus testing. The consequences of the potential virus exposure of manufacturing processes as well as the effectiveness of mitigation efforts are discussed. The pharmaceutical supply chain is complex, traversing many geographies and companies that range from large multinationals to mid- and small-size operations. This paper recommends practices that can be adopted by all companies, irrespective of their size, geographic location, or position in the supply chain.


Introduction

During academic training, every microbiologist learns about pandemics and their impact on society. However, this bookish knowledge, although foundational, does not prepare one for all the potential contingencies and scenarios that a pandemic can present. As of the writing this article, there is no approved drug to treat COVID-19 infection and a shortage of testing capabilities to identify the virus in people exhibiting symptoms of infection and to screen for viral antibodies to determine infected individuals who have recovered and might have immunity and return to the workplace. It should be noted that several health authorities have given emergency authorization for use of certain drugs and antibody tests. Further, because of the global increase in demand and the disruption in transportation, the COVID-19 pandemic has resulted in major shortage of medicines needed to treat symptoms of the disease, manage pain, or to prevent or control secondary infections. See the Food and Drug Administration (FDA) Drug Shortage website for additional information (1). In addition, the pandemic has created a shortage of supplies of disinfectants and sanitizers and personal protective equipment (PPE) such as masks and gowns needed to meet good manufacturing practice (GMP) standards and associated standard operating procedures (SOPs).

Over the last 20 years, the world has experienced outbreaks of major novel respiratory infectious diseases such as the SARS (Severe Acute Respiratory...
Syndrome) outbreak (2002), influenza H1N1 pandemic (2009), and MERS (Middle East Respiratory Syndrome) outbreak (2012), and now the COVID-19 pandemic (2020). Pandemics can disrupt pharmaceutical supply in multiple ways at a time when medicines and vaccines are critically needed to control the pandemic and treat medical conditions not related to respiratory illness in other patients. Unavailability of raw materials, manufacturing supplies, shutdown of transportation systems, and most importantly employee absenteeism owing to infections, suspected infections, or fear of infections can disrupt supply. The U.S. FDA published Guidance for Industry—Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products (2) in March 2011, that is, following the 2009 Influenza H1N1 pandemic. More recently, the Medicines and Healthcare products Regulatory Agency, United Kingdom (MHRA) (3) and the World Health Organization (WHO) (4) have published guidance on flexibilities in response to the COVID-19 pandemic. Since the last pandemic in 2009, there has been a massive global increase in the use of social media platforms as a source of information, which may or may not be accurate and can result in poor decisions that can impact the drug supply.

This article reviews currently available scientific information related to coronaviruses and disinfectants from peer-reviewed journals, authenticated sources such as the U.S. federal Centers for Disease Control and Prevention (CDC), FDA, WHO, major health authorities, and national and international GMP standards. Although the article is primarily directed toward pharmaceutical drug manufacturing, the content should be useful to all manufacturers of over-the-counter drug products, consumer health products, cosmetics, and medical devices. The question asked is how potential risks can be identified and mitigated to protect our manufacturing facilities, employees, drug products, and customers from this pandemic respiratory virus? It should be noted that the COVID-19 pandemic is fast moving, and a tremendous amount of new scientific knowledge is being created every day. The authors have endeavored to make recommendations based on an anticipated progression of the pandemic in general terms, although the effect of the pandemic locally and internationally may vary. In addition, local laws, regulations, and other requirements will inform each company’s specific response to the pandemic.

**Potential Risks That Can Result in Drug Shortages**

The potential risk associated with COVID-19 can be categorized into direct risk posed by the virus to employees and to product and indirect risk to manufacturing and distribution activities materialized by policies and controls promulgated by local, state, and national governments to control the pandemic (Figure 1).

To assess the direct risk posed by COVID-19, it is important to understand the epidemiology, infectivity, and susceptibility to disinfection.

**Epidemiology of the COVID-19 Pandemic and Related Outbreaks**

The 2019 novel coronavirus that was identified as the cause of an outbreak of respiratory illness is now referred to as the COVID-19 pandemic with the infectious viral agent designated as SARS-CoV-2. It was
first detected in Wuhan, China, on December 12, 2019 (5) and reported to the WHO China Country Office on December 31, 2019 (6). By mid-January, COVID-19 spread to Thailand, Japan, and Korea and then to Europe.

As the rapid spread of SARS-CoV-2 in the U.S.A. is well documented in the published literature, the authors have used the U.S. as the basis for discussion. The first documented U.S. case was a 34-year-old man who traveled to Wuhan, China to visit family, returned, and reported to an urgent care clinic in Snohomish County, Washington on January 19, 2020, in response to a health alert from the U.S. CDC (7). On March 11, 2020, the WHO declared Coronavirus Disease 2019 (COVID-19) a pandemic (WHO Statement, 2020) as it had spread to multiple countries with high prevalence of community transfer. On January 31, 2020, the U.S. federal Health and Human Service (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS (8). In addition, on March 13, 2020, the President of the United States declared a national emergency in response to COVID-19 (9).

By the end of March, there were 240,000 confirmed U. S. cases with over 7000 deaths, resulting in the declaration of a national emergency by the President of the United States, with orders for nonessential workers to work from home. By the end of April, there were over 1 million U.S. confirmed cases and 60,000 deaths. Pharmaceutical employees involved in production and testing activities were deemed essential globally; health authorities issued requests for pharmaceutical industry to work to avoid drug shortages.

**Description of the SARS-CoV-2 Virus**

Coronaviruses are lipid-enveloped, single-stranded, positive sense RNA viruses, with 26 to 32 kilobases, belonging to the genus *Coronavirus*, which includes several relatively benign, seasonal, common cold viruses and three new, more virulent coronaviruses: severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in the human population in 2003; Middle East Respiratory Syndrome coronavirus (MERS-CoV), which emerged in humans during 2012; and SARS-CoV-2 that emerged in late 2019 and became the COVID-19 pandemic in early 2020 (10–12)

Enveloped viruses like SARS-CoV-2 are highly susceptible to cleaning agents and disinfectants, above ambient temperature, and usually do not survive on inanimate surfaces beyond 2 days. This will be discussed in more detail in the section on persistence of SARS-CoV-2. The individual coronavirus particles are around 0.125 μm in diameter. N95 face masks are rated to capture 95% of particles down to 0.3 μm. This means that viral particles may still potentially get through this protection. The virus appears to be dispersed as larger droplets or aerosols and the multiple layers of the face masks largely mitigates this risk. In contrast, HEPA filters are 99.97% effective at 0.3 μm and thus are much more efficient than face masks.

**Sources of the SARS-CoV-2 Virus**

Zoonotic respiratory viruses initially emerge by animal-to-human and then largely by human-to-human transmission and to a lesser degree surface-to-human transmission. Dense human populations coexisting with dense chicken, duck, and pig populations as found in the People’s Republic of China, as well as the consumption of wild animals as food, favors the emergence of novel respiratory viruses (13, 14). There is little or no evidence that the coronavirus is either a foodborne or waterborne viral pathogen.

Foodborne viral pathogens are responsible for a larger number of illnesses than bacterial pathogens annually. They may be classified into three main groups of viral illnesses: viruses that cause gastroenteritis, for example, norovirus and rotavirus; enterically transmitted hepatitis viruses, for example, hepatitis A; and enteroviruses, for example, poliovirus (15). Notably foodborne viruses are not associated with respiratory infection.

According to a March 2020 WHO Interim Guidance (16), although SARS-CoV-2 persistence in drinking water is possible, there is evidence from surrogate human coronaviruses that they are not present in surface or ground water sources or transmitted through contaminated drinking water. The coronavirus, an enveloped virus with a fragile outer membrane, does not survive in the environment and would be susceptible to filtration and chlorine treatment before water distribution.

Because SARS-CoV-2 may be shed in fecal matter (up to 10% confirmed presence in diarrhea) with some
earlier reports of fecal-to-oral transmission (17, 18),
this route of transmission should not be treated casu-
ally, and personnel hygiene should be emphasized in
manufacturing facilities.

Public health experts have ruled out the possibility of
insect-to-human transmission.

Personnel Health and Safety

The biggest risk to the community at large, and as such
to the pharmaceutical supply chain, is human-to-human
transmission of the coronavirus. Protecting the health
and safety of employees should be the top priority of
companies. The following points should be considered
and as appropriate built into the pandemic response
plans developed by individual companies.

Social Distancing and Work from Home

Certain local, state, and national governments and their
health authorities have issued social distancing guide-
lines that may include a mandatory stay at home order
with a caveat to exclude “essential employees,” that is,
employees necessary to keep critical services and
activities in operation. To our knowledge, all govern-
ments combating the pandemic have classified “phar-
maceutical employees” as essential workers. As such,
pharmaceutical companies generally have the liberty to
determine what employees, if any, should work from
home and who should report to work. The authors rec-
ommend companies develop a comprehensive contin-
gency plan to identify essential activities and the
employees needed to execute such activities. Support
staff in quality assurance (QA), regulatory affairs, pur-
chasing, human resources, research and development,
planning, sales and marketing, and general manage-
ment largely may work from home. Staff directly
employed in manufacturing operations, quality control
testing, engineering and maintenance, security, ware-
housing, and shipping must be on site and potentially
expose each other, facilities, and products to viral
contamination.

The employees identified as essential will depend on
the manufacturing sites ability to conduct GMP activ-
ities remotely via a 21 CFR Part 11 compliant informa-
tion technology (IT) system. For example, sites that
have completely electronic batch records may not need
to have a QA batch record reviewer on site, but those
that have paper records or hybrid paper and paperless
systems may need to include such an employee on the
list of essential employees.

Furthermore, the determination of which employees
are considered essential will depend, in part, on the
level of community spread. For example, site auditors
may not be considered essential if the virus threat level
is high within the local community, but as the threat
decreases, auditors may be included in the list of essen-
tial employees.

Employees working off-site, using communication
tools like mobile telephones, e-mail, and videoconfer-
cencing, can conduct many support activities in the
pharmaceutical industry. This will significantly reduce
the numbers of employees on-site. In terms of the drug
product supply chain, such employees may be viewed
as nonessential, whereas those employees (operators,
operator managers, as well as managers) directly involved in product man-
ufacturing, testing, and distribution are viewed as
essential. However, this distinction is not clear-cut. For
example, it may be possible to delay a supplier audit of
a pharmaceutical ingredient used in the manufacture of
an essential drug product, annual GMP training for
packaging operators, or even marketed product stabil-
ity testing. Determining what are nonessential activ-
ities and what are essential must be approached in a
well-considered manner. The authors recommend that
companies develop pandemic contingency plans that
mandate essential activities and provide justification
and timelines for the completion of activities that are
delayed as nonessential. These plans should be ap-
proved by their quality control unit and may, impor-
tantly, be subject to regulatory review.

Identification of Infected Employees

As we believe that the biggest risk to the supply chain
is person-to-person viral transmission followed by sur-
face-to-person transmission, the most important risk
mitigation will be excluding infected employees, espe-
cially those manufacturing, sampling, and testing drug
products, from the pharmaceutical workplace to main-
tain the workforce and not potentially cause product
contamination.

GMP regulations, for example 21 CFR 211.28 d states:

Any person shown at any time (either by medi-
cal examination or supervisory observation) to
have an apparent illness or open lesions that
may adversely affect the safety or quality of drug products shall be excluded from direct contact with components, drug product containers, closures, in-process materials, and drug products until the condition is corrected or determined by competent medical personnel not to jeopardize the safety or quality of drug products. All personnel shall be instructed to report to supervisory personnel any health conditions that may have an adverse effect on drug products.

As such, pharmaceutical companies are required to have procedures in place and a training program for employees to self-report and supervisors to observe and detect illness.

The major symptoms of COVID-19 infection are dry cough, fever, and difficulty breathing, but asymptomatic sufferers may shed the virus (19). All employees who self-identify as sick must be encouraged to stay home and report their status to their immediate supervisor and seek medical help. Examples of high-risk factors include sick family members and friends, recent foreign and domestic travel, attendance at events with large crowds such as arena concerts and professional sport games, frequenting places of worship, schools, restaurants, social clubs, and bars, dwelling in high-density population cities and towns, and commuting using public transportation.

To maximize the possibility that employees will self-report potential illness, the authors recommend reviewing sick-leave policies for all employees, including temporary and contract workers. We also recommend that companies enhance general awareness about the symptoms of COVID-19 by reinforcing the need for self-reporting and supervisory vigilance.

**Screening Pharmaceutical Employees at the Point of Entry to Manufacturing Facilities**

Recent epidemiological studies of COVID-19 suggest that infected individuals may remain asymptomatic or presymptomatic for up to 2 weeks (21). Therefore, in addition to reinforcing GMP requirements to self-report illness, companies should consider instituting procedures to screen employees entering manufacturing facilities. Such procedures need to be developed in accordance with government-mandated requirements and employee rights to privacy, avoidance of discrimination, and respect for existing employee contracts and union agreements.

On April 23, 2020, the U.S. Equal Employment Opportunity Commission (EEOC) issued an update to its guidance that now expressly acknowledges that employers may test employees for COVID-19 and conduct temperature-screening measures without violating the provisions of the Americans with Disabilities Act (ADA) or the Rehabilitation Act (20). According to the EEOC, “an employer may choose to administer COVID-19 testing to employees before they enter the workplace to determine if they have the virus.” Further, as stated by the EEOC:

Consistent with the ADA standard, employers should ensure that the tests are accurate and reliable. For example, employers may review guidance from the U.S. Food and Drug Administration about what may or may not be considered safe and accurate testing, as well as guidance from CDC or other public health authorities, and check for updates. Employers may wish to consider the incidence of false-positives or false-negatives associated with a particular test. Finally, note that accurate testing only reveals if the virus is currently present; a negative test does not mean the employee will not acquire the virus later.

The EEOC guidance applies only with respect to the two specified federal statutes in the U.S. We recommend that companies in the U.S. also consider the applicability of relevant state and local law and consult legal counsel as needed before initiating a mandatory employee-testing program. Companies outside the U.S. must obviously consider applicable national and local laws.

Also, in the U.S., the federal Occupational Safety and Health Administration (OSHA) recommends that companies develop an Infectious Disease Preparedness and Response Plan (22). The OSHA updated recommendations state the following:

If one does not already exist, develop an infectious disease preparedness and response plan that can help guide protective actions against COVID-19. Stay abreast of guidance from federal, state, local, tribal, and/or territorial health agencies, and consider how to incorporate those recommendations and resources into workplace-specific plans. Plans should consider and address the level(s) of risk associated with various worksites and job tasks workers perform at those sites.
How can employees be screened? Depending on the nature of the workforce, and the confidence and trust management has in the workforce, companies should decide whether to institute mandatory testing and/or institute self-screening or screening during entrance into the plant site.

If screening is performed during entrance to your plant sites, the employees’ entry should be staggered to maintain social distancing and prevent delays. In addition to any mandatory COVID-19 testing that may be adopted, the authors believe in their expert opinion that the screening may consist of the following activities:

1. Monitor the body temperature of all employees. If self-monitoring is permitted, employees could check their body temperature using a personal clinical thermometer just prior to leaving for work. Employees should not report to work and should seek medical advice immediately if their body temperature is above 100.4°F/38°C. If screening is conducted at the plant entrance, a trained screener should use a calibrated handheld or wall-attached no-touch thermometer. Employees with a body temperature exceeding 100.4°F/38°C should be segregated and not allowed to enter the facility.

2. Conduct brief interviews of potentially SARS-CoV-2-infected employees to identify those with the common symptoms of fever, dry cough, and difficulties breathing.

3. Take a travel and contact history of a suspected infected employee for the past 14 days to determine the potential for contamination of the manufacturing facility and infection of other employees.

4. Segregate any potentially infected employees and encourage them to get medical care through their regular physician or neighborhood medical center. It would be useful to provide employees with healthcare contact information.

5. Obtain a commitment from the employee to report their medical status and results of any testing for the presence of the coronavirus when they update their sick leave status according to company policy.

6. Determine whether the infected employee’s co-workers within social distancing need to be quarantined from the workplace.

7. Determine the potential impact on the manufacturing operation as a result of employee absences.

8. When an employee is confirmed positive for the coronavirus, clean and disinfect the locations directly impacted in their workspace and other high-traffic areas like bathrooms, break rooms, hallways, and entrances.

9. Review of the frequency of employee exclusions by a local oversight committee to determine the need for self-quarantine of potentially infected employees, institute additional risk mitigations, and determine the potential impact to the manufacturing schedule.

The recommended screening listed as 1 through 6 will have recognizable limitations. Multiple screening methods will most likely be more effective than a single method. Clinical thermometers may be in short supply during a pandemic. Studies on the use of infrared thermal image scanners in influenza and COVID-19 airport screening (23–25) to identify infected travelers showed that, compared to virus testing, they might detect less than half of those infected because of the viral incubation period and asymptomatic individuals. Screening each day of entrance to the workplace as compared to a departure or arrival screening at an airport will increase its effectiveness. A recent publication on the presenting characteristics of 5700 patients hospitalized with COVID-19 in the New York City area (26) found that only 31% had an elevated temperature, 17% rapid breathing, and 43% rapid heart rate. No information on the incidence of body ache and coughing was provided. This variability in symptoms will make screening more challenging. Based on these findings, companies are cautioned not to place too much reliance on only temperature screening. Another report from a Northern California hospital system indicated that the chief symptoms in 377 adults when presenting in the emergency department were 49% shortness of breath, 34% fever, and 32% cough (27).

As testing for the SARS-CoV-2 virus to detect infected individuals and the antibody to detect individuals who have been infected and recovered becomes widespread, companies should consider offering testing on a voluntary basis as an effective tool for keeping their workforce. Based on a PDA membership survey (In press) apparently most employees would accept this offer of screening. The best method of managing this testing will become apparent as infectious disease experts gain
more experience managing the pandemic and the subsequent return to work.

Facility and Process Management

Persistence of Coronavirus on Inanimate Surfaces

Human viruses cannot multiply outside of the body and will not survive on inanimate surfaces for long. An analysis of 22 studies on the persistence of human coronaviruses other than SARS-CoV-2 virus (Table I) reveals that they may persist on metal, glass, or plastic for up to 9 days (range 2 h to 9 days), but they are readily inactivated within 1 min by disinfectants and sporicides such as 62%–71% ethanol, 0.5% hydrogen peroxide, or 0.1% sodium hypochlorite (28).

The studies summarized in Table I have their technical limitations as they used related coronaviruses but not SARS-CoV-2, different types of inoculum preparations, high inoculum levels, different storage conditions, and reverse transcription polymerase chain reaction assays as a measure of survival and not infectious units determined by cell culture methods. However, until additional studies are conducted with the SARS-CoV-2 virus, these will be indicative and will contribute to our analysis.

Other agents used in the pharmaceutical industry, including the antiseptics 0.05%–0.2% benzalkonium chloride and 0.02% chlorhexidine digluconate, are less effective, requiring a contact time of up to 10 min (28). These findings will strictly limit the ability of novel coronaviruses to contaminate the pharmaceutical supply chain.

A more recent March 17, 2020, letter to the New England Journal of Medicine analyzed the aerosol and surface stability of SARS-CoV-2 (COVID-19) and
compared this stability to that of SARS-CoV-1, its most closely related coronavirus (29). The authors of the letter reported 10 experimental conditions, conducted in triplicate, involving the two viruses in five environmental conditions, that is aerosols, inoculated plastic, stainless steel, copper, and cardboard. SARS-CoV-2 remained viable as measured by median tissue culture infectious dose for 50% of the cells to be infected (TCID$_{50}$) in the aerosol suspension for the 3 h duration of the experiment with a reduction in infectious titer from $10^{3.7}$ to $10^{2.7}$ TCID$_{50}$/mL, representing a half-life of 1.1–1.2 h. In a controlled environment with many air changes per hour, the virus would be readily removed from the air.

The coronavirus was more stable on plastic and stainless steel than on copper and cardboard. Although the virus could be detected for up to 72 h, its titer was greatly reduced (from $10^{3.7}$ to $10^{0.6}$ TCID$_{50}$/mL after 72 h on plastic and from $10^{3.7}$ to $10^{0.6}$ TCID$_{50}$/mL after 48 h on stainless steel). On copper, apparently because of Cu$^{2+}$ toxicity, no viable SARS-CoV-2 was measured after 4 h and on cardboard, no viable SARS-CoV-2 was measured after 8 h (29). This means, that in the event that controls established to exclude an infected employee fail, and in the event that packaged product is exposed to the virus, the plastic container used for primary packaging and the cardboard used for secondary packaging should not carry infectious coronavirus because of the amount of time the drug products will be advancing through the supply chain. Therefore, pharmaceutical products are very unlikely to pose any risk of infecting pharmacists dispensing, medical staff administering, and patients taking such products.

The relationship between temperature and relative humidity and the survival of coronaviruses in aerosols and on surfaces has been investigated. Enveloped viruses were found to survive longer at lower temperatures and humidity and may persist longer in refrigerators and cold rooms (30–32). The efficacy of pasteurization (63°C for 30 min) was demonstrated with MERS-CoV in camel, goat, and cow milk with the virus titer reduced from $10^{5.5}$ to $<10^{0.5}$ TCID$_{50}$ (33). Clearly, the heat sensitive SARS-CoV-2 virus will not survive sterilization processes used in sterile product manufacturing.

Inactivation of Viruses Owing to Routine Cleaning and Disinfection

The coronavirus may be physically removed from a surface with a particle-free wipe, inactivated by detergents in cleaning agents, or inactivated by disinfectants and sporicides. In addition to routine cleaning and sanitization programs established to meet GMP requirements designed to protect product, companies should establish cleaning and sanitization of surfaces in non-GMP areas, including hallways, bathrooms, offices, and other common areas, to protect the health and safety of employees during the pandemic. The controls, qualification, and documentation requirements for GMP activities should be well-established and subject to change control and/or planned deviation. Such controls are not required for sanitization programs designed for the non-GMP areas.

The frequency of cleaning and disinfection of an area in a GMP manufacturing facility will depend on the intensity of traffic in the area and the exposure of personnel to drug product manufacturing. This frequency may range from weekly, to daily, to before and after each shift. It should be emphasized that cleaning to remove grime and product residues prior to the application of disinfectants is critical for their best efficacy. Table II, although not exhaustive as the U. S. Environmental Protection Administration (EPA) List N (34) which contains 75 agents, provides useful information on representative commercially available products, their active ingredients, contact times, and antiviral claims.

Cleaning and disinfection are considered critical GMP processing steps especially in sterile product manufacturing subject to process validation (see 2004 FDA Aseptic Processing Guideline). Guidance on the qualification of individual disinfectants and sporicidal agents may be found in USP &Disinfectants and Antiseptics (35). Media reports highlight the shortage of disinfectants and hand sanitizers. Under the current circumstance, it is the expert opinion of the authors that on an interim basis, alternate suppliers may be identified and a like-for-like substitution made, forgoing process validation and a vendor audit to make up for the shortage. Critical elements for making this like-for-like selection of an alternative source of a disinfectant include reputation of the supplier, active ingredient, active ingredient concentration, EPA and other national registration, efficacy claims, whether the disinfectant formulation is diluted before use or a ready-for-use product, and sterilization by gamma irradiation. To alleviate the shortage of hand sanitizers, the FDA has authorized the in-house production of alcohol hand sanitizers (36), but the authors believe that these materials should not be used in the critical ISO 5 aseptic processing areas.
<table>
<thead>
<tr>
<th>Active Ingredient</th>
<th>Product Name</th>
<th>Company</th>
<th>Contact Time (Minutes)</th>
<th>Formulation Type</th>
<th>Emerging Antiviral Claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrogen Peroxide</td>
<td>Accel (Concentrate)</td>
<td>Virox Technology</td>
<td>5</td>
<td>Dilutable</td>
<td>Yes</td>
</tr>
<tr>
<td>Phenolic</td>
<td>LpH</td>
<td>Steris</td>
<td>10</td>
<td>Dilutable</td>
<td>Yes</td>
</tr>
<tr>
<td>Phenolic</td>
<td>Vesphene II se</td>
<td>Steris</td>
<td>10</td>
<td>Dilutable</td>
<td>Yes</td>
</tr>
<tr>
<td>Sodium Hypochlorite</td>
<td>CloroxPro™ Clorox® Germicidal Bleach</td>
<td>Clorox Professional Product Co.</td>
<td>5</td>
<td>Dilutable</td>
<td>Yes</td>
</tr>
<tr>
<td>Isopropyl alcohol</td>
<td>DECON-AHOL WFI® Formula 70%</td>
<td>Veltek Associates</td>
<td>NA</td>
<td>RTU</td>
<td>No</td>
</tr>
<tr>
<td>Hydrogen Peroxide and Peracetic Acid</td>
<td>DECON-SPORE 200® Plus</td>
<td>Veltek Associates</td>
<td>NA</td>
<td>RTU</td>
<td>No</td>
</tr>
<tr>
<td>Quaternary Ammonium;Ethanol</td>
<td>Lysol® Disinfectant Spray</td>
<td>ReckittBenckiser LLC</td>
<td>5</td>
<td>RTU</td>
<td>Yes</td>
</tr>
<tr>
<td>Hydrogen Peroxide</td>
<td>Oxy-1 Wipes</td>
<td>Vorox Technology</td>
<td>0.5</td>
<td>Wipes</td>
<td>Yes</td>
</tr>
<tr>
<td>Ethanol</td>
<td>PURELL Professional Disinfectant Wipes</td>
<td>GOJO Industries</td>
<td>5</td>
<td>Wipes</td>
<td>Yes</td>
</tr>
<tr>
<td>Sodium Hypochlorite</td>
<td>Clorox Healthcare® Bleach Germicidal Wipes</td>
<td>Clorox Professional Products Co.</td>
<td>3</td>
<td>Wipes</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Viral Clearance by HVAC Systems and HEPA Filters in Clean Rooms

Warehouses, offices, laboratories, and manufacturing and packaging areas in a pharmaceutical manufacturing plant will be served by heating, ventilating, and air conditioning (HVAC) systems to maintain targeted temperature, humidity, and numbers of air changes appropriate for each of these areas. In addition, clean rooms and other controlled areas where sterile drug products are manufactured are supplied with high-efficiency particulate air (HEPA)-filtered air to meet specified air cleanliness levels as well as more stringent requirements for temperature, relative humidity, space pressurization, and number of air changes per hour to prevent product contamination.

In general, the level of environmental control, the PPE worn by clean room operators, and the cleaning and disinfection program will make it unlikely that the coronavirus will persist in clean rooms and contaminate sterile drug products (37). This leaves questions around areas served solely by conventional HVAC systems without HEPA filtration.

The 2014 American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE) Position Document (38) highlights that some infectious diseases including those caused by coronaviruses are transmitted through the inhalation of airborne infectious particles, which can be disseminated through buildings by pathways that include ventilation systems. This transmission may be reduced using dilution ventilation, directional airflow, room pressure differentials, source capture ventilation, air filtration, and ultraviolet germicidal irradiation (UVGI), as well as appropriate cleaning and disinfection practices.

The ASHRAE document addresses control strategies (38). In a practical application, a combination of the individual interventions will be more effective than a single intervention in isolation. It is recommended that a heating and air-conditioning engineer be consulted on the implementation of these strategies. Pharmaceutical companies may consider improving particle filtration for the central air handler, adding upper-room UVGI units, increasing the outdoor ventilation rates, and avoiding the use of a lower ventilation rate motivated solely by reduced energy consumption.

Small aerosolized particles, < 10 μm, generated by talking, coughing, or sneezing will be suspended in the air and transported into the lower respiratory tract during breathing whereas larger drops, 10–25 μm, will fall through the air and accumulate on horizontal surfaces (39). Aerosols may be transported some distance by sideways airflows in non-classified rooms, whereas vertical laminar airflow with floor-level exit registers will sweep the air clean in classified clean rooms. Table III provides information on the number of air changes per hour.

We believe that pharmaceutical manufacturing conducted in classified areas (ISO 8 to ISO 5) will provide environmental conditions that will adequately clear viral particles potentially shed by employees. Nonclassified areas where non-sterile drug products are manufactured and all packaging and labeling areas will need to be assessed for the number of air changes (ventilation rate) to facilitate viral clearance and for their cleaning and disinfection practices. Based on this risk assessment, changes may be necessary.

Hand Sanitization

Hand washing and sanitization are an essential component of GMP controls designed to protect product. In addition to these routine controls, additional hand sanitization stations should be established in non-GMP areas to mitigate risk to employees.

### Table III

<table>
<thead>
<tr>
<th>Class of Clean room</th>
<th>Airflow Type</th>
<th>Average Velocity (Ft./Min.)</th>
<th>Air Changes/hr.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISO 8 (Class 100,000)</td>
<td>N/M</td>
<td>1–8</td>
<td>5–48</td>
</tr>
<tr>
<td>ISO 7 (class 10,000)</td>
<td>N/M</td>
<td>10–15</td>
<td>60–90</td>
</tr>
<tr>
<td>ISO 6 (Class 1,000)</td>
<td>N/M</td>
<td>25–40</td>
<td>150–240</td>
</tr>
<tr>
<td>ISO 5 (Class 100)</td>
<td>U/N/M</td>
<td>40–80</td>
<td>240–480</td>
</tr>
</tbody>
</table>

N is Non-unidirectional; M is Mixed Airflow; U is Unidirectional. Note: 10 ft/min equals 3.048 m/min.
TABLE IV

Appropriate Personal Protective Equipment for Routine Pharmaceutical Manufacturing (40)

<table>
<thead>
<tr>
<th>Protective Clothing</th>
<th>Non-Sterile Manufacturing Areas</th>
<th>Sterile Manufacturing Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plant uniform or plant uniform with overalls for high-risk product and environment</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Hair/beard coverings</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Safety glasses</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Dedicated shoes or shoe coverings</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Gloves</td>
<td>Yes (if in direct product contact)</td>
<td>Yes</td>
</tr>
<tr>
<td>Face masks</td>
<td>Yes (if in direct product contact)</td>
<td>Yes</td>
</tr>
<tr>
<td>Enclosed respirators</td>
<td>Only if manufacturing high-potency, toxic drugs or infectious biological agents</td>
<td>Only if manufacturing high-potency, toxic drugs or infectious biological agents</td>
</tr>
<tr>
<td>Sterile clean room uniforms (coveralls), hoods, sleeves, goggles, face masks, and gloves</td>
<td>No</td>
<td>Yes, if in critical aseptic processing area</td>
</tr>
</tbody>
</table>

Personal Protective Equipment

As COVID-19 infected individuals cannot be absolutely excluded from our manufacturing sites, PPE will become more important. A decision should be made whether the workplace wearing of face masks would be mandatory or limited to those activities in which personnel have direct contact with drug products. Table IV addresses the appropriate PPE to be worn during non-sterile and sterile drug product manufacturing.

The efficacy of different grades of face masks in entrapping COVID-19 viral particles has not been fully established. The level of exposure to coworkers, processing equipment, and pharmaceutical drug products may determine the choice from homemade face masks to cone masks, to medical face masks to N95 grade face masks (respirators).

The specifications for different grades of face masks obtained from commercial supply catalogs may include:

2. Bacterial Filtration: >92%, >95%, or >99% @ 1.0 μm particle size retention
3. Reduced Particle Generation: Layers ultrasonically welded to limit particle shedding
4. Effective Pore Size: 1.0, 0.45, or 0.1 μm
5. Usage: Disposable, single use, or re-usage
6. Sterility: Non-sterile or sterile

FDA Regulation of Face Masks as Medical Devices

The FDA regulates face masks and respirators when they meet the definition of a device under section 201 (h) of the federal Food, Drug, and Cosmetic Act (FD&C Act). Generally, face masks fall within this definition when they are intended for a medical purpose, including for use by health care professionals (41). These classifications are useful in determining which devices should be used in a pharmaceutical manufacturing facility.

The FDA defines these devices that may be suitable for use in a GMP manufacturing facility as follows:

Face Mask—A mask, with or without a face shield, that covers the user’s nose and mouth and may or may not meet fluid barrier or filtration efficiency levels.

Surgical Mask—A mask that covers the user’s nose and mouth and provides a physical barrier to fluids and particulate materials. The mask meets certain fluid barrier protection standards and Class I or Class II flammability tests.
N95 Respirator—A disposable half-mask filtering face piece respirator (FFR) that covers the user’s airway (nose and mouth) and offers protection from particulate materials at an N95 filtration efficiency level per 42 CFR 84.181. Such an N95 FFR used in a health care setting is regulated by the FDA under 21 CFR 878.4040 (FDA product code MSH) and is either a Class II device that is exempt from premarket notification requirements under section 510(k) of the FD&C Act or is a Class II cleared device.

NIOSH Approved N95 Respirator—An N95 respirator, approved by National Institute for Occupational Safety and Health, that meets filtration efficiency level per 42 CFR 84.181.

The following are devices suitable for use in a clinical setting when medical staff treat COVID-19-infected patients but not in pharmaceutical manufacturing:

Face Shield—A face shield is a device used to protect the user’s eyes and face from bodily fluids, liquid splashes, or potentially infectious materials. Generally, a face shield is situated at the crown of the head and is constructed with plastic to cover the user’s eyes and face.

Filtering Face Piece Respirator—A filtering face piece respirator (FFR) is a device that is a disposable half-face-piece nonpowered air-purifying particulate respirator intended for use to cover the nose and mouth of the wearer to help reduce wearer exposure to pathogenic biological airborne particulates.

Surgical N95 Respirator—A disposable FFR used in a health care setting that is worn by health care personnel (HCP) during procedures to protect both the patient and the HCP from the transfer of microorganisms, body fluids, and particulate material at an N95 filtration efficiency level per 42 CFR 84.181. A surgical N95 respirator is regulated by the FDA under 21 CFR 878.4040 (FDA product code MSH) and is either a Class II device that is exempt from premarket notification requirements under section 510(k) of the FD&C Act or is a Class II cleared device.

Given the CDC recommendation that in addition to social distancing, face masks should be worn when people leave their places of residence, pharmaceutical companies should require employees reporting to work to be wearing face masks and should supply nonmedical masks to be worn on company premises until this recommendation is lifted. These face masks would be replaced at least twice a day and disposed as potential biohazard waste.

In manufacturing areas where pharmaceutical ingredients, packaging components, intermediates, and finished products are exposed to workers, the PPE recommendations found in Table IV would be strictly followed.

Pharmaceutical companies as high-volume users of face masks may employ strategies to conserve these devices when they are in short supply. These include allowing employees to use homemade cloth face masks to enter their facilities and continue to wear them in office areas, allowing the removal of face masks in isolated offices that maintain strict social distancing, and, when strictly necessary, the reuse of surgical masks after decontamination. On April 9, 2020, the FDA issued an Emergency Use Authorization (EUA) for the emergency use of a Steris Corporation vapor-phase hydrogen peroxide sterilization system for decontaminating compatible N95 respirators for reuse by medical personnel to prevent potential exposure to pathogenic airborne particulates when the respirators are in short supply because of the COVID-19 pandemic. The data submitted by Steris supported up to 10 sterilizations and reuse. It was noted that cellulose-based face masks are incompatible with hydrogen peroxide (42).

**Vaccines against the SARS-CoV-2 Virus**

The availability of safe and effective vaccines would help relax employee screening, social distancing practices, and the use of PPE in non-GMP areas. More than 40 different vaccines are in development globally with at least two now in Phase I human safety trials as of April 22, 2020. Vaccine clinical development is a complex process, which requires large clinical trials and establishing the long-term safety of the vaccine. The history of vaccine development is replete with examples of safety signals emerging post approval as a result of unexpected immunological response post immunization, for example, Rotashield and Dengvaxia. Further, it should be noted that there is no approved vaccine for SARS-COV-1 and for MERS, outbreaks that occurred in 2002 and 2012, respectively. Because of the widespread disease, recruiting large number of subjects for clinical trials is not expected to be a hurdle for COVID-19 vaccines, but this may change as the pandemic recedes. Despite all-out efforts, Dr. Anthony Fauci, Director of the U.S. National Institute of Allergy...
and Infectious Diseases, predicts that the availability of a vaccine will take a year to a year and a half, at least (43).

**Regulatory Responses**

*Regulatory Response to the COVID-19 Outbreak*

On February 11, 2020, when the WHO formalized the name of the current outbreak as COVID-19, the FDA immediately added this official disease on their website. This new FDA Webpage will soon fill up with a wide range of guidance documents and directives in a very short time. This COVID-19 outbreak has generated an unprecedented response from the FDA and other U.S. regulatory agencies to remove many regulatory hurdles that were hindering the Industry response efforts to monitor and treat this pandemic. These dramatic changes from the global compliance norm reflect the seriousness of this viral threat to our medical supply industry along with the safety of those who work in these industries and those who may be patients in need of these pharmaceutical medical products. Among these U.S. federal agencies are the FDA, the CDC, OSHA, and the NIH. Their general contribution to the mitigation and relief of regulatory formalities will be briefly described following. In a February 14, 2020, press release, the FDA announced that “if a potential shortage or disruption of medical products is identified by the FDA, we will use all available tools to react swiftly and mitigate the impact to U.S. patients and health care professionals”. At this time period, the FDA press releases were focused on the impact of medicine and product coming from China owing to the COVID-19 outbreak that was occurring in that area of the world. It is very unlikely at that time that the pharmaceutical industry or regulators knew how significantly the subsequent global pandemic would impact their routine activities. Subsequently, there has been a significant list of FDA initiatives to minimize the shortage of essential medicine within the U. S. because of active pharmaceutical ingredient (API) unavailability for the manufacturing of the finished products (FDA announcement date February 27, 2020). Included in this list are the following guidance documents and directives and their date of issuance:

1. Critical human drug shortages can be mitigated with lengthening the expiration dates. (FDA, February 27, 2020).
2. A new policy for certain laboratories that develop and begin to use validated COVID-19 diagnostics before the FDA has completed review of their EUA request (FDA, February 29, 2020).
3. The FDA and Federal Trade Commission (FTC) issued seven warning letters to companies for selling fraudulent COVID-19 products. The products cited in these warning letters are teas, essential oils, tinctures, and colloidal silver. (FDA, March 9, 2020).
4. Coronavirus (COVID-19) Update: The FDA issues Guidance for Conducting Clinical Trials. The FDA is aware that protocol modifications may be required, and that there may be unavoidable protocol deviations owing to COVID-19. This would eventually include expedited early vaccine trial for the development of a COVID-19 vaccine (FDA, March 18, 2020).
5. The FDA and National Institutes of Health (NIH) have begun a randomized controlled trial for the treatment of COVID-19 patients with the investigational antiviral drug Remdesivir; interleukin-6 receptor inhibitors; as well as the application of convalescent plasma and hyperimmune globulin, antibody-rich blood products that are taken from blood donated by people who recovered from the virus infection (FDA, March 19, 2020).
7. The FDA provides maximum flexibility to importers seeking to bring PPE into the U.S. with minimal disruptions during the importing process. The agency provided instructions to manufacturers on how to inform the U.S. Customs and Border Protection with specific advisement to expedite regulatory clearance. (FDA, March 24, 2020).
8. The FDA issues an EUA to allow for the emergency use in health care settings of certain ventilators, anesthesia gas machines modified for use as ventilators, and positive pressure breathing devices modified for use as ventilators (FDA, March 27, 2020).
9. The FDA establishes a new program to expedite the development of potentially safe and effective life-saving treatments. The program is known as the Coronavirus Treatment Acceleration Program (CTAP). This public-private approach is cutting red tape, redeploying FDA staff, and working day and night to review requests from companies, scientists, and doctors who are working toward therapies. (March 31, 2020).

10. The FDA issued a new EUA for non-NIOSH-approved respirators made in China, which makes KN95 respirators eligible for authorization if certain criteria are met. (FDA, April 3, 2020).

The authors of this review applaud the FDA in providing a more flexible regulatory response to the pandemic. However, caution should be mentioned as to the temporary nature of these allowable regulatory shortcuts during this pandemic, and the return to standard practice should be documented to prevent any regulatory citations made by health authority inspections as the urgency of this historic event diminishes over time.

### European Union Regulatory Expectations during the COVID-19 Pandemic

As with the FDA in the United States, we are seeing a strong regulatory response to the COVID-19 pandemic from other regions of the world (43). For example, the combined organizations of the European Commission (EC), Heads of Medicines Agencies (HMA), and the European Medicines Agency (EMA) have published a Notice to their Stakeholders. The document is entitled “Questions and Answers on Regulatory Expectations for Medicinal Products for Human Use During the COVID-19 Pandemic” (EU Q&A document, April 2020). We will not discuss the entire Q&A in this review article, but we will highlight some key responses that the European Union (EU) expressed in their handling of deviations in manufacturing and importation of finished products and API as they relate to GMP and good documentation practice (GDP) issues during this pandemic.

Among some of the temporary changes include: (1) measures should be put in place to ensure the validity of GMP certificates that support manufacture and importation of medicinal products into the EU should be extended to avoid disruptions in the availability of medicines, with a liberal time extension to sites located inside the EU; (2) with the difficulty to perform on-site GDP inspections, the validity of GDP certificates will be extended until the end of 2021 with no further company action required; (3) remote batch certification and remote audits of API manufacturers have been expanded, even for those EU companies previously disallowed from this process; and (4) in case of imports of investigational medicinal products from outside of the EU, the companies quality department should ensure that the quality of the batch is in accordance with the terms of the clinical trial authorization and meets EU GMP requirements. The EMA recommended to make this assessment remotely; the companies need to review documents including batch records, in-process test reports, validation status of facilities, the results of any analyses performed after importation, stability reports, storage and shipping conditions, and so forth. Most gratifying was the response to the question can quality requirements be waived/adapted for medicines intended to be used for the treatment of COVID-19 patients? The short answer to this question was “No” but with the EMA offer that if manufacturers were having difficulties performing the compliance quality control steps, they were invited to contact the competent authorities and “to present an adapted control scheme based on a risk-based approach”. There was additional information to help navigate the regulatory hurdles posed by the restrictive travel conditions during this pandemic, so a review of the entire document is suggested for those manufacturing and conducting business in the EU geographic areas.

### Overall Risk Assessment

#### Risk Analysis Tools

A number of risk analysis tools, including quality risk management, may be used when assessing risk factors. Tables S-I to S-VI (see Appendix) show an example of a hazard analysis and critical control points (HACCP) program approach (originating in the food industry), which summarizes the common inputs, identifies the various risks with ratings from low to high, and suggests common risk mitigations or critical process control points. Risk assessment of the specific steps in the supply chain for a representative non-sterile and sterile drug product, that is, activity, risk level, critical control point, and mitigation are provided (44).

Steps analyzed included staff recruitment, procurement of pharmaceutical ingredients and packaging components, facility design and operation, cleaning and...
disinfection, utilities, manufacturing processes, packaging and labeling, warehousing, shipment, dispensing, and patient usage.

Drug Shortages

A major responsibility of the pharmaceutical industry and regulators is to anticipate and meet the changed demands for drug products driven by patient treatment and disruption to our supply chain. This statement appeared recently on the FDA website https://www.fda.gov/drugs/drug-safety-and-availability/guidance-notifying-fda-permanent-discontinuance-or-interruption-manufacturing-under-section-506c-fdc.

“Due to the COVID-19 pandemic, FDA has been closely monitoring the medical product supply chain with the expectation that it may be impacted by the COVID-19 outbreak, potentially leading to supply disruptions or shortages of drug and biological products in the U.S. The guidance, Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing Under Section 506C of the FD&C Act, is intended to help applicants and manufacturers provide the agency with timely and informative notifications about changes in the production of certain drugs and biological products. In urging the submission of these notifications, the guidance may assist in our efforts to prevent or mitigate shortages of such products, including under circumstances outside of the COVID-19 public health emergency.”

Many pharmaceutical drug products have the potential to be in short supply because of increased demand to treat hospitalized COVID-19 patients. Shifting production schedules to meet this increasing demand will help but may create backorders for other needed drugs. The disruption to the supply chain because of absenteeism among line employees preventing the manufacture, testing, and distribution of drug products and not product contamination.

Shortages have been reported for drugs that are used to keep patients’ airways open, as well as antibiotics, antivirals, and sedatives (45–47). In March 2020, orders for broad-spectrum antibiotics like azithromycin and antivirals like ribavirin have tripled; medicines for sedation and pain management like fentanyl, midazolam, and propofol have increased by 100%, 70%, and 60%, respectively.

Risk Assessment

The authors believe that as SARS-CoV-2 is a communicable human respiratory virus, the largest risk to the supply chain is absenteeism among line employees preventing the manufacture, testing, and distribution of drug products and not product contamination.

There are gaps in our knowledge of the epidemiology of the COVID-19 pandemic around identifying at-risk populations and the role of antibodies in preventing repeat infection that when filled will help manage our workforce (48).

The cell culture-based manufacturing processes of biological medicinal products can, and has in several instances, been infected by viruses (49). The susceptibility of the currently used manufacturing platforms, such as cell lines CHO, HT1080, and HEK 293 for the new SARS-CoV-2 has already been tested though, and the cell lines were found nonpermissive, that is do not support viral growth, to this new virus (Kreil, 2020 Personal Communication). See Table V for a summary of the lack of capacity of the coronavirus to grow in commonly used cell lines.

The detectability of the new SARS-CoV-2 has also been tested, and the cell line panels used in standard in vitro adventitious virus testing as required by regulatory guidance (ICH Q5A (R1)) were found capable of revealing virus presence (Kreil, 2020 Personal Communication). As might have been expected from experience with the earlier SARS-CoV, the Vero cell line was highly susceptible to infection, which was easily visible by development of a cytopathic effect (49).

The three main risks for viral contamination in cell culture for therapeutic production are the cell source, materials used in cell culture, and exposure of the process stream to the operators or environment with viral clearance, that is, inactivation or removal from the product, being most important in reducing the risk of virus contamination of the finished product. The reader is referred to the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) study for more details on risk mitigation (49).

Discussion

The objective of our discussion will primarily focus on the unique current conditions and problems associated
with the controls to minimize disruption of the pharmaceutical supply chain and to highlight other factors that we may not have had the available information to include in this review publication. Future data and experiences will eventually fill in the gaps of our current understanding and control of the COVID-19 pandemic.

The 2020 COVID-19 global pandemic meets all the characteristics of “A Black Swan”, what the best-selling author Nassim Nicholas Talab defined as an event with low probability, extreme impact, unforeseen, and retrospective predictability (51). Dr. Talab, a renowned Professor of Risk and Decision Science, proposed the Black Swan theory to explain highly improbable events, and the bias in decision-making introduced by past experience and by pockets of knowledge not available to all decision makers.

### Low Probability Events

As per the WHO, in 2016 lower respiratory infections were the deadliest communicable disease, causing 3 million deaths worldwide, and were the fourth overall on the top 10 global causes of death (52). As per the CDC, in 2017 influenza and pneumonia were the leading cause of communicable disease, causing 55,672 deaths in the U.S., and were the eighth overall on the top 10 causes of death (53). Although scientists understood the possibility of another novel, highly contagious, and deadly respiratory virus outbreak, past experience gained in managing SARS-CoV-1, H1N1 influenza, and MERS outbreaks that had limited spread may have introduced a bias among some scientists, policy makers, and the public at large in assessing probability and underestimating the rapid spread of the COVID-19 outbreak into a pandemic.

### Extreme Impact Events

The medical impact of a pandemic has been well studied by scientists; however, the impact of mitigation strategies such as social distancing, and the impact of a global end to transportation and the resulting economic activity was perhaps not well understood and anticipated. As such, the scientific, medical, business, and legal communities had to scramble to find quick solutions and remedies to both the direct and indirect deleterious impact from this pandemic. The essential nature of the pharmaceutical industry to combat pandemics and its higher level of knowledge and awareness, regulatory requirement to have business continuity plans, regulatory relief, and GMP controls has resulted in relatively less impact on the manufacturing activities of pharmaceutical companies as compared to many other manufacturing and service industries.

### Unforeseen Events

The complexity of the supply chain, the increased demand for PPE, and the inability of essential employees to commute to work during stay-at-home orders were unforeseen domino effects. When national catastrophes (i.e., tornadoes, hurricanes, forest fires) occur in certain regions of a country there are generally local, state, or federal contingency plans in place to mitigate or coordinate the multiresponse to that affected area. Pandemics being relatively rare events, and each having unique characteristics and speed of spread, can result in many unanticipated challenges.

---

**TABLE V**

Capacity of SARS-CoV-2 to Replicate in Primate and Human Cell Lines

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Cell Line Origin</th>
<th>SARS-CoV Replication</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHO</td>
<td>Chinese Hamster Ovary</td>
<td>Incompatible</td>
<td>(Kreil, 2020 Personal Communication)</td>
</tr>
<tr>
<td>HEK293</td>
<td>Human Embryonic Cells</td>
<td>Incompatible</td>
<td>(Kreil, 2020 Personal Communication)</td>
</tr>
<tr>
<td>HT1080</td>
<td>Human fibrosarcoma</td>
<td>Incompatible</td>
<td>(Kreil, 2020 Personal Communication)</td>
</tr>
<tr>
<td>A549</td>
<td>Human Adenocarcinoma Cells</td>
<td>Incompatible</td>
<td>50</td>
</tr>
<tr>
<td>HUH</td>
<td>Human Liver Cells</td>
<td>Moderate</td>
<td>50</td>
</tr>
<tr>
<td>HEK293T</td>
<td>Human Embryonic Cells</td>
<td>Moderate</td>
<td>50</td>
</tr>
<tr>
<td>VERO</td>
<td>African Green Monkey Kidney Cells</td>
<td>High</td>
<td>50</td>
</tr>
</tbody>
</table>

*aIncompatible is no growth, no cytopathic effect (CPE); Moderate is growth but no CPE; High is growth and CPE.*
**Retrospective Predictability**

As the pandemic progresses, it is easy to connect the dots and conclude that the pandemic was predictable and that different decisions were required. The fast spread of a novel virus requires decision-making on limited information and decisions need to be reevaluated as new information becomes available. There needs to be a deliberate and educated infectious disease preparedness and response plan built into business continuity plans for the next inevitable pandemic.

**Limited Viral Characterization and Transmission Factors**

One of our knowledge gaps as it relates to this infectious virus is our inability to identify asymptomatic infected individuals and exclude them from the pharmaceutical workplace without widespread testing for the virus and its antibodies. This would be followed by the problem with a lack of follow-up contact investigations. Lastly, a more definitive assessment of the efficacy of PPE, especially face masks, against the SARS-CoV-2 virus is needed.

**Current Industry Manufacturing Practices That Are Low Risk**

In general, because of the reduced ability of the lipid-enveloped virus to survive (but not proliferate) outside the human body, clean room environmental controls, cleaning and disinfection programs, and the PPE employed in the pharmaceutical industry are adequate to prevent COVID-19 viral contamination of our sterile products manufactured in GMP-compliant facilities and do not need to be changed. Our review includes recent information that the COVID-19 virus does not grow in the conventional manufacturing cell lines used for the proliferation and production of biologically based pharmaceutical products (Kriel, 2020 Personal Communication)

**Risk Mitigation Steps That May Need Reevaluation**

Areas that may need a closer risk assessment may be environmental conditions and controls in non-sterile product manufacturing rooms and all product labeling and packaging areas. The engineering and operational standards of the HVAC systems supplying these workspaces should be reviewed and, if necessary, improved. Parameters that may need to be assessed may include the number of air changes per hour, cleaning and disinfection programs, and the PPE worn in these areas. Because of the low risk of viral contamination of our GMP-controlled pharmaceutical equipment and manufacturing rooms, no product testing for the presence of the COVID-19 virus is recommended. Until COVID-19 is better understood, employees holding staff positions should work from home. Protocols for the eventual integration of the total work force back to pre-COVID-19 activity need to be written and reviewed, which should include medical and legal staff to allow for the gradual and specific viral monitoring with a cognizant determination for those who are at highest risk to this virus. The reliability of the medical platform for making these determinations should be assessed. For example, the benefit of measurable antibody blood titers to the COVID-19 virus may not be a 100% reliable factor for preventing reinfection by this virus.

**Critical Risk Mitigation Steps That Should Be Evaluated**

Pharmaceutical companies must aggressively screen their employees for COVID-19 infection and remove those infected, in a timely manner, from the workplace. These actions are necessary to avoid absenteeism because of continuing infection or reinfection of critical employees and the general work staff and a loss of employees to manufacture, test, and distribute essential drug products. A more definitive list of the risk mitigation steps recommended by the authors will be presented in the next section.

**Conclusions**

The authors, from their point-of-view as microbiologists, have attempted to review the risks and recommend mitigation steps that pharmaceutical companies, depending on their circumstances, should consider implementing in their manufacturing facilities.

The PDA has established a COVID-19 task force with broader representation of the disciplines within our membership that expand on areas over and above this review.

**Recommendations**

The following risk mitigation steps to minimize the impact of COVID-19 on the pharmaceutical supply
chain based on the risk classification in Figure 1 are recommended.

Direct Risks Posed by the COVID-19 Pandemic

Personal Health and Safety

1. To facilitate social distancing, employees able to do their job from home should be allowed to do so while employees directly involved in the manufacture, testing, packaging, and distribution of pharmaceutical product should be screened for potential COVID-19 infection and if suspected to be infected should be excluded from the workplace.

2. Nonessential visitors should be denied entry to all manufacturing facilities.

3. Additional hand sanitation stations should be installed in non-GMP areas.

4. Wearing of face masks by all employees in non-GMP areas should be considered after careful evaluations of the risks and benefits and would not be governed by GMP procedures.

5. If a safe and efficacious COVID-19 vaccine is available, it should be made widely available to the manufacturing employees of pharmaceutical companies.

Product Quality

1. Meeting GMP requirements related to PPE and excluding at risk employees from manufacturing activities will provide adequate assurance.

2. Testing for the presence of COVID-19 in manufacturing facilities and products is not recommended.

3. Pharmaceutical GMPs should be strictly maintained.

4. Determine if mammalian cell lines used for biopharmaceutical production are not susceptible to the COVID-19 virus.

5. Pharmaceutical companies are encouraged to actively monitor recommendations from the U.S. CDC an FDA, the EMA, and the WHO and make changes to their policies and procedures as the COVID-19 pandemic recedes.

GMP Manufacturing

1. Environmental controls, the appropriate use of PPE, and cleaning and disinfectant practices, especially in warehouses, non-sterile manufacturing areas, and packaging lines should be reviewed and updated if necessary.

2. Manufacturing and testing schedules can be adjusted and additional shifts added to facilitate social distancing and to ensure essential drug products are not in short supply.

Availability of Supplies

1. Strategies for conserving face masks and other PPE should be implemented.

2. Enhance collaboration with suppliers, educating them about their importance to the pharmaceutical industry.

Indirect Risks Posed by the COVID-19 Pandemic

Availability of Employees

1. Repurpose employees for critical activities.

2. Supply alternative transportation for employees who commute to work using public transportation.

Transportation Infrastructure

1. Distribute finished goods using dedicated transportation in place of common carriers.

Regarding the availability of raw materials, for example, drug substances, excipients, solvents, processing supplies, and packaging materials:

1. Strengthen existing supplier relations.

2. Seek alternative suppliers.

Acknowledgments

The authors wish to thank T. Cosgrove, Esq., and A. Caruso for their assistance in writing the article, and the members of the PDA COVID-19 Task Force for their review and helpful comments.
Disclaimer

The opinions and suggestions made by the authors in this manuscript do not necessarily reflect the policies and requirements of their affiliated companies.

References


34. EPA List N: Products with Emerging Viral Pathogens and Human Coronavirus Claims for Use against SARS-CoV-2: Date Accessed: 03/28/2020


Appendix

HACCP Approach to Risk Assessment
A comprehensive risk assessment of the different parts of the pharmaceutical supply chain may be found in Tables S-VI–S-XI. The four columns in each table address the input or activity, potential risk identification, assigned risk rating (low, moderate, or high), and existing critical process controls and recommended risk mitigations. The risk assessment model used is based on food-based HACCP principles that may be unfamiliar to some people working in the pharmaceutical industry (45). These represent the informed opinions of the authors with an emphasis on the risk assessment process and an attempt to capture all relevant aspects of the steps in the supply chain.

TABLE S-I
Risk Assessment—Management of Human Resources during COVID-19 Pandemic

<table>
<thead>
<tr>
<th>Activity</th>
<th>Risk Identification</th>
<th>Risk Rating</th>
<th>Risk Mitigation/Critical Process Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recruitment of new staff</td>
<td>Local; Regional; National; International</td>
<td>Low to Moderate</td>
<td>Remote interviews; Limit domestic and international travel; 14-day quarantine prior to starting work</td>
</tr>
<tr>
<td>Training new hires and existing employees</td>
<td>Lack of information; Issues not addressed in corporate policies and procedures</td>
<td>Moderate to High</td>
<td>GMP compliance; Coronavirus awareness training; Symptoms identification</td>
</tr>
<tr>
<td>Deployment of employees</td>
<td>Domestic; International</td>
<td>Moderate to High</td>
<td>Staff functions conducted from home; Restrictions on nonessential domestic and international travel; deferment of large staff meetings</td>
</tr>
<tr>
<td>Management and Supervision of Employees</td>
<td>Staff and line functions</td>
<td>Moderate to High</td>
<td>Illness recognition; Monitoring with thermal sensors; Universal wearing of non-medical face masks on the job</td>
</tr>
<tr>
<td>Employee Attendance</td>
<td>Employees working sick; Loss of human resources; Inability to commute</td>
<td>Low</td>
<td>Flexibility in working hours; Stress importance of staying home when ill; Provide sickness benefits; Add company sponsored transportation when public transportation is unavailable</td>
</tr>
</tbody>
</table>
TABLE S-II
Risk Assessment—Management of Manufacturing Materials during COVID-19 Pandemic

<table>
<thead>
<tr>
<th>Materials</th>
<th>Risk Identification</th>
<th>Risk Rating</th>
<th>Risk Mitigation/Critical Process Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical Excipients</td>
<td>Excipients derived from plant, animal, or mineral origin; Excipients of synthetic or semisynthetic origin</td>
<td>Low</td>
<td>Supplier awareness of potential COVID-19 risk; Standard duration of transit and hold times</td>
</tr>
<tr>
<td>Drug Substances</td>
<td>Drug substance of synthetic or semisynthetic origin</td>
<td>Low</td>
<td>Standard duration of transit and hold times</td>
</tr>
<tr>
<td>Packaging Components</td>
<td>Glass vials, stoppers and seals (Sterile products)</td>
<td>Low</td>
<td>Standard duration of transit and hold times; automation of component handling; washing, depyrogenation and sterilization (sterile products)</td>
</tr>
<tr>
<td></td>
<td>Plastic container, heat induction seals and caps (non-sterile products)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling Materials</td>
<td>Labels and package inserts</td>
<td>Low</td>
<td>Reduce handling during label identification and reconciliation</td>
</tr>
<tr>
<td>Incoming Potable Water</td>
<td>Ground or surface water</td>
<td>Low</td>
<td>Communication with local water authority</td>
</tr>
</tbody>
</table>

TABLE S-III
Risk Assessment—Testing of Incoming Pharmaceutical Ingredients, Packaging Components, Intermediates, and Finished Products during COVID-19 Pandemic

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sampling of incoming materials</td>
<td>Human intervention; Limited environmental controls in warehouses</td>
<td>Moderate</td>
<td>Personal protective equipment; sampling booths; labeling sampled containers</td>
</tr>
<tr>
<td>Transportation to the testing area</td>
<td>Transition through the facility</td>
<td>Low</td>
<td>Disinfection of the surface of containers, drums, shrink-wrap, and pallets</td>
</tr>
<tr>
<td>Sample testing</td>
<td>Personnel handling</td>
<td>Low</td>
<td>Personal protective equipment; limited access to testing area; environmental controls</td>
</tr>
<tr>
<td>Sample disposition</td>
<td>Disposal</td>
<td>Low</td>
<td>Controlled destruction of samples</td>
</tr>
<tr>
<td>Materials—Plant Utilities</td>
<td>Risk Identification</td>
<td>Risk Rating</td>
<td>Risk Mitigation/Critical Process Controls</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Pharmaceutical-grade water</td>
<td>Incoming potable water</td>
<td>Low</td>
<td>Maintain existing microbial monitoring program</td>
</tr>
<tr>
<td>Pharmaceutical-grade plant air</td>
<td>Distribution lines and delivery nozzles</td>
<td>Low</td>
<td>Assure sanitary design</td>
</tr>
<tr>
<td>Compressed gases</td>
<td>None</td>
<td>Low</td>
<td>Maintain existing microbial monitoring program</td>
</tr>
<tr>
<td>HVAC system</td>
<td>Poor temperature, humidity, and air exchange; Recirculation and lack of segregation</td>
<td>Low to Moderate</td>
<td>Reduced recirculation in more critical areas; Higher air change rates; High room ultraviolet germicidal irradiation</td>
</tr>
<tr>
<td>Domestic and clean steam</td>
<td>None</td>
<td>Low</td>
<td>None</td>
</tr>
<tr>
<td>Vacuum</td>
<td>Discharge</td>
<td>Low</td>
<td>Review vacuum discharge</td>
</tr>
<tr>
<td>Washing facilities</td>
<td>Poor design and opportunities for cross-contamination</td>
<td>Low to Moderate</td>
<td>Access to detergents, hot water, and hand sanitizing agents; Segregation of clean and dirty materials</td>
</tr>
<tr>
<td>Waste and sewage disposal</td>
<td>Poor separation</td>
<td>Moderate</td>
<td>Backflow elimination; Segregation of clean and dirty materials</td>
</tr>
</tbody>
</table>
### TABLE S-V
Risk Assessment—Representative Non-Sterile Drug Product (Compressed Tablet) during COVID-19 Pandemic

<table>
<thead>
<tr>
<th>Manufacturing Process</th>
<th>Risk Identification</th>
<th>Risk Rating</th>
<th>Risk Mitigation/Critical Process Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incoming material sampling and testing</td>
<td>Sampling is an invasive process</td>
<td>Moderate</td>
<td>Sampling booths; Personal protective equipment (PPE)</td>
</tr>
<tr>
<td>Warehousing</td>
<td>Limited environmental control</td>
<td>Low</td>
<td>Improved environmental control</td>
</tr>
<tr>
<td>Ingredient weighing</td>
<td>Weighing is an invasive process</td>
<td>Low to Moderate</td>
<td>Evaluate weighing booths and PPE</td>
</tr>
<tr>
<td>Excipient size reduction</td>
<td>Equipment cleaning</td>
<td>Low</td>
<td>Upgrade COP and CIP operations</td>
</tr>
<tr>
<td>Blending</td>
<td>Equipment cleaning</td>
<td>Low</td>
<td>Upgrade COP and CIP operations</td>
</tr>
<tr>
<td>Granulation—Dry</td>
<td>Equipment cleaning</td>
<td>Low</td>
<td>Upgrade COP and CIP operations</td>
</tr>
<tr>
<td>Granulation—Wet</td>
<td>Equipment cleaning</td>
<td>Low</td>
<td>Upgrade COP and CIP operations</td>
</tr>
<tr>
<td>Compression</td>
<td>Equipment cleaning</td>
<td>Low</td>
<td>Upgrade COP and CIP operations</td>
</tr>
<tr>
<td>Bulk Tablet Storage</td>
<td>None</td>
<td>Low</td>
<td>None</td>
</tr>
<tr>
<td>Packaging and labeling</td>
<td>Packaging operations are labor intensive</td>
<td>Low to Moderate</td>
<td>Evaluate HVAC Systems; Automation of component handling; PPE</td>
</tr>
<tr>
<td>Finished goods warehousing</td>
<td>Poor environmental control</td>
<td>Low</td>
<td>Improved environmental control</td>
</tr>
<tr>
<td>Shipping</td>
<td>Lack of chain of custody</td>
<td>Low</td>
<td>Dedicated carriers</td>
</tr>
</tbody>
</table>

Clean Out-of-Place (COP) and Clean In-Place (CIP).
TABLE S-VI
Risk Assessment—Representative Sterile Drug Products (Liquid-filled Stoppered Glass Vials) during COVID-19 Pandemic

<table>
<thead>
<tr>
<th>Manufacturing Process</th>
<th>Risk Identification</th>
<th>Risk Rating</th>
<th>Risk Mitigation/Critical Process Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incoming material sampling and testing</td>
<td>Sampling is an invasive process in a warehouse</td>
<td>Moderate</td>
<td>Sampling booths and personal protective equipment (PPE)</td>
</tr>
<tr>
<td>Warehousing</td>
<td>Limited environmental control</td>
<td>Low</td>
<td>Improved environmental control (IEC)</td>
</tr>
<tr>
<td>Ingredient weighing</td>
<td>Weighing is a labor-intensive process</td>
<td>Low to Moderate</td>
<td>Evaluate weighing booths and PPE</td>
</tr>
<tr>
<td>Bulk solution preparation</td>
<td>Solution preparation is a potentially invasive process</td>
<td>Low to Moderate</td>
<td>Use of Restricted Access Barrier Systems (RABS) and isolators</td>
</tr>
<tr>
<td>Packaging component preparation</td>
<td>Component loading and unloading is a potentially invasive process</td>
<td>Low</td>
<td>Automation of component handling; Depyrogenation and sterilization of vials and stoppers</td>
</tr>
<tr>
<td>Sterile filtration and aseptic filling and Sealing</td>
<td>Aseptic processing is a potentially invasive process</td>
<td>Low</td>
<td>Use of RABS and isolators</td>
</tr>
<tr>
<td>Visual inspection</td>
<td>Inspection is an invasive process</td>
<td>Low</td>
<td>Handling automation; IEC; PPE</td>
</tr>
<tr>
<td>Packaging and labeling</td>
<td>Packaging is an invasive process</td>
<td>Low</td>
<td>Handling automation; IEC; PPE</td>
</tr>
</tbody>
</table>
An Authorized User of the electronic PDA Journal of Pharmaceutical Science and Technology (the PDA Journal) is a PDA Member in good standing. Authorized Users are permitted to do the following:

- Search and view the content of the PDA Journal
- Download a single article for the individual use of an Authorized User
- Assemble and distribute links that point to the PDA Journal
- Print individual articles from the PDA Journal for the individual use of an Authorized User
- Make a reasonable number of photocopies of a printed article for the individual use of an Authorized User or for the use by or distribution to other Authorized Users

Authorized Users are not permitted to do the following:

- Except as mentioned above, allow anyone other than an Authorized User to use or access the PDA Journal
- Display or otherwise make any information from the PDA Journal available to anyone other than an Authorized User
- Post articles from the PDA Journal on Web sites, either available on the Internet or an Intranet, or in any form of online publications
- Transmit electronically, via e-mail or any other file transfer protocols, any portion of the PDA Journal
- Create a searchable archive of any portion of the PDA Journal
- Use robots or intelligent agents to access, search and/or systematically download any portion of the PDA Journal
- Sell, re-sell, rent, lease, license, sublicense, assign or otherwise transfer the use of the PDA Journal or its content
- Use or copy the PDA Journal for document delivery, fee-for-service use, or bulk reproduction or distribution of materials in any form, or any substantially similar commercial purpose
- Alter, modify, repackage or adapt any portion of the PDA Journal
- Make any edits or derivative works with respect to any portion of the PDA Journal including any text or graphics
- Delete or remove in any form or format, including on a printed article or photocopy, any copyright information or notice contained in the PDA Journal

PDA Journal
of Pharmaceutical Science and Technology

Authorized User or for the use by or distribution to other Authorized Users

Authorized Users are not permitted to do the following: